MedTrace Logo

Doxecitine and Doxribtimine-Expanded Access

NCT06590493 · Status: AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2025-09-12

No results posted yet for this study

Summary

This Expanded Access Record for doxecitine and doxribtimine includes the following managed access programs and status:

TK0113: Available TK0115: Available

Conditions

  • Thymine Kinase 2 Deficiency

Interventions

DRUG

doxecitine and doxribtimine

TK0113 and TK0115: Doxecitine and doxribtimine is dosed daily and will be administered orally or via feeding tube. The patient may continue to receive doxecitine and doxribtimine treatment within the EAP as long as the benefit / risk balance remains positive in the opinion of the treating physician or access to commercially available doxecitine and doxribtimine, when it becomes available.

Sponsors & Collaborators

  • UCB BIOSCIENCES, Inc.

    lead INDUSTRY

Principal Investigators

  • UCB Cares · 001 844 599 2273

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06590493 on ClinicalTrials.gov